ストックスクリーナーアプリを入手
63.35
4.25%
2.58
前日終値:
$60.77
開ける：
$60.99
24時間の取引高:
1.62M
Relative Volume:
0.81
時価総額：
$7.75B
収益：
$18.47M
当期純損益:
$-589.53M
株価収益率:
-12.04
EPS:
-5.26
ネットキャッシュフロー:
$-399.80M
1週間 パフォーマンス:
-3.53%
1か月 パフォーマンス:
-3.93%
6か月 パフォーマンス:
+90.81%
1年 パフォーマンス:
+26.11%
1日の値動き範囲:
$60.45
$63.80
1週間の範囲:
$59.56
$66.37
52週間の値動き範囲:
$29.31
$69.33
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.35 | 7.43B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - BioCentury
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com UK
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - sharewise.com
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out - ACCESS Newswire
Is Cytokinetics Incorporated (KK3A) stock overpriced at current multiplesMarket Trend Report & Long-Term Capital Growth Ideas - Newser
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bakersfield.com
Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Sold by Schroder Investment Management Group - MarketBeat
Why analysts recommend Cytokinetics Incorporated (KK3A) stockJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
What technical patterns form on Cytokinetics Incorporated (KK3A) stock chartsPortfolio Risk Summary & Short-Term Swing Trade Alerts - Newser
How Cytokinetics Incorporated (KK3A) stock trades under stagflation2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
Cytokinetics, Incorporated $CYTK Position Increased by American Century Companies Inc. - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,200 Shares - MarketBeat
Henderson, Cytokinetics director, sells $559k in stock By Investing.com - Investing.com South Africa
Edward Md Kaye Sells 28,064 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics, Incorporated $CYTK Stake Cut by Skandinaviska Enskilda Banken AB publ - MarketBeat
Can Cytokinetics Incorporated (KK3A) stock sustain margin levelsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Cytokinetics, Incorporated $CYTK Shares Sold by Fisher Asset Management LLC - MarketBeat
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused fundsJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Can Cytokinetics Incorporated (KK3A) stock attract ESG investmentsMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Henderson, Cytokinetics director, sells $559k in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $559,125, According to a Recent SEC Filing - marketscreener.com
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 08 '25 |
Sale |
65.96 |
1,042 |
68,730 |
50,660 |
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 05 '25 |
Option Exercise |
33.84 |
52,486 |
1,775,998 |
103,146 |
| Callos Andrew | EVP, Chief Commercial Officer |
Dec 05 '25 |
Sale |
65.95 |
52,486 |
3,461,452 |
50,660 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):